SearcharxivSearch

arXiv subjects

Peter Vestergaard

Publications and source records attributed to Peter Vestergaard.

2 recordsLinked to original sources

Personalized Forecasting of Glycemic Control in Type 1 and 2 Diabetes Using Foundational AI and Machine Learning Models

Background: Accurate week-ahead forecasts of continuous glucose monitoring (CGM) derived metrics could enable proactive diabetes management, but relative performance of modern tabular learning approaches is incompletely defined. Methods: We trained and internally validated four regression models (CatBoost, XGBoost, AutoGluon, tabPFN) to predict six weekahead CGM metrics (TIR, TITR, TAR, TBR, CV, MAGE, and related quantiles) using 4,622 case-weeks from two cohorts (T1DM n=3,389; T2DM n=1,233). Performance was assessed with mean absolute error (MAE) and mean absolute relative difference (MARD); quantile classification was summarized via confusion-matrix heatmaps. Results: Across T1DM and T2DM, all models produced broadly comparable performance for most targets. For T1DM, MARD for TIR, TITR, TAR and MAGE ranged 8.5 to 16.5% while TBR showed large MARD (mean ~48%) despite low MAE. AutoGluon and tabPFN showed lower MAE than XGBoost for several targets (e.g., TITR: p<0.01; TAR/TBR: p<0.05 to 0.01). For T2DM MARD ranged 7.8 to 23.9% and TBR relative error was ~78%; tabPFN outperformed other models for TIR (p<0.01), and AutoGluon/ tabPFN outperformed CatBoost/XGBoost on TAR (p<0.05). Inference time per 1,000 cases varied markedly (PFN 699 s; AG 2.7 s; CatBoost 0.04 s, XGBoost 0.04 s). Conclusions: Week-ahead CGM metrics are predictable with reasonable accuracy using modern tabular models, but low-prevalence hypoglycemia remains difficult to predict in relative terms. Advanced AutoML and foundation models yield modest accuracy gains at substantially higher computational cost.

q-bio.OT

Glucose-insulin mathematical model for the combined effect of medications and life style of Type 2 diabetic patients

The goal of this paper is to propose a new mathematical model for the combined effect of different treatments and lifestyles on the glucose-insulin dynamics of Type 2 diabetes (T2D) patients. The model gives the possibility to take into consideration physical activity, stress, meals, and medications while evaluating or designing treatment plans for T2D patients. The model is proposed by combining and modifying some of the available models in the literature. Simulations were performed for the modifications to show how the model confirm with literature on T2D patients. Additionally, a discussion is provided to demonstrate the ability of the model to be used in the assessment of treatment plans and in the design for robust insulin dose guidance algorithms. An open source code for the model is additionally provided.

eess.SY